COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
Heather I HendersonDavid Alain WohlWilliam A FischerLuther A BarteltDavid Van DuinDeana M AgilLindsay E BrowneKuo-Ping LiAmanda MoyJoseph J EronSonia NapravnikPublished in: The Journal of antimicrobial chemotherapy (2024)
COVID-19 hospitalization risk was reduced by 84% among nirmatrelvir/ritonavir recipients in a large, diverse healthcare system during the Omicron wave. These results suggest that nirmatrelvir/ritonavir remained highly effective in a setting substantially different than the original clinical trials.